MiR-181a-2-3p as a potential diagnostic and prognostic marker for myelodysplastic syndrome

References

• Tefferi A, Vardiman JW. Myelodysplastic Syndromes. N Engl J Med. 2009;361:1872–1885.
   PubMed Web of Science ®Google Scholar
• Nolte F, Hofmann W-K. Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol. 2010;6(3):445–455.
   PubMed Web of Science ®Google Scholar
• Milunovic V, Rogulj IM, Planinc-Peraica A, et al. The role of microRNA in myelodysplastic syndromes: beyond DNA methylation and histone modification. Eur J Haematol. 2016;96(6):553–563.
   PubMed Web of Science ®Google Scholar
• Pfeilstöcker M, Tuechler H, Sanz G, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128(7):902–910.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–3627.
   PubMed Web of Science ®Google Scholar
• Pati H, Veetil KK. Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes: molecular pathogenetic mechanisms and their implications. Ind J Hematol Blood Transf. 2019;35(1):3–11.
   PubMed Web of Science ®Google Scholar
• Cargo CA, Rowbotham N, Evans PA, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood. 2015;126(21):2362–2365.
   PubMed Web of Science ®Google Scholar
• Theilgaard-Mönch K, Boultwood J, Ferrari S, et al. Gene expression profiling in MDS and AML: potential and future avenues. Leukemia. 2011;25:909–920.
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Fidler C, Wainscoat JS, et al. Gene expression profiling in the myelodysplastic syndromes. Hematology. 2005;10(4):281–287.
   PubMed Web of Science ®Google Scholar
• Kuang X, Chi JLW. Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes. Hematology. 2016;21(10):593–602.
   PubMed Web of Science ®Google Scholar
• Wallace JA, O’Connell RM. MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts. Blood. 2017;130(11):1290–1301.
   PubMed Web of Science ®Google Scholar
• Alemdehy MF, Erkeland SJ. MicroRNAs: key players of normal and malignant myelopoiesis. Curr Opin Hematol. 2012;19(4):261–267.
   PubMed Web of Science ®Google Scholar
• Liao R, Xu Y, Chen M, et al. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia. Hematology. 2013;18(4):191–197.
   PubMed Web of Science ®Google Scholar
• Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009;50(2):472–480.
   PubMed Web of Science ®Google Scholar
• Niu J, Xue A, Chi Y, et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene. 2016;35(10):1302–1313.
   PubMed Web of Science ®Google Scholar
• Bisso A, Faleschini M, Zampa F, et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle. 2013;12(11):1679–1687.
   PubMed Web of Science ®Google Scholar
• Taylor MA, Sossey-Alaoui K, Thompson CL, et al. TGF-beta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest. 2013;123(1):150–163.
   PubMed Web of Science ®Google Scholar
• Huang P, Ye B, Yang Y, et al. MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2. Tumour Biol. 2015;36(5):3381–3387.
   PubMedGoogle Scholar
• Huang SX, Zhao ZY, Weng GH, et al. Upregulation of miR-181a suppresses the formation of glioblastoma stem cells by targeting the Notch2 oncogene and correlates with good prognosis in patients with glioblastoma multiforme. Biochem Biophys Res Commun. 2017;486(4):1129–1136.
   PubMed Web of Science ®Google Scholar
• Chhabra R. let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer. Sci Rep. 2018;8(1):7840.
   PubMedGoogle Scholar
• Liu T, You X, Sui J, et al. Prognostic value of a two-microRNA signature for papillary thyroid cancer and a bioinformatic analysis of their possible functions. J Cell Biochem. 2018. Online ahead of print. doi:10.1002/jcb.27993.
   Web of Science ®Google Scholar
• Rahul Agrawal PP, Jha P, Dwivedi V, et al. Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing. BMC Genomics. 2014;15(1):686.
   PubMedGoogle Scholar
• Yin J, Li X, Zhang Z, et al. SPAG6 silencing induces apoptosis in the myelodysplastic syndrome cell line SKM–1 via the PTEN/PI3K/AKT signaling pathway in vitro and in vivo. Int J Oncol. 2018;53(1):297–306.
   PubMed Web of Science ®Google Scholar
• Wan C, Wen J, Huang Y, et al. Microarray analysis of differentially expressed microRNAs in myelodysplastic syndromes. Medicine (Baltimore). 2020;99(27):e20904.
   PubMed Web of Science ®Google Scholar
• Henao-Mejia J, Williams A, Goff LA, et al. The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity. 2013;38(5):984–997.
   PubMed Web of Science ®Google Scholar
• Braicu C, Gulei D, Raduly L, et al. Altered expression of miR-181 affects cell fate and targets drug resistance-related mechanisms. Mol Aspects Med. 2019;70:90–105.
   PubMed Web of Science ®Google Scholar
• Rezaei T, Amini M, Hashemi ZS, et al. microRNA-181 serves as a dual-role regulator in the development of human cancers. Free Radic Biol Med. 2020;152:432–454.
   PubMed Web of Science ®Google Scholar
• Guo Y, Strickland SA, Mohan S, et al. MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. Leuk Lymphoma. 2017;58(9):1–15.
   Web of Science ®Google Scholar
• Su R, Lin HS, Zhang XH, et al. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene. 2015;34(25):3226–3239.
   PubMed Web of Science ®Google Scholar
• Nanbakhsh A, Visentin G, Olive D, et al. miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells. Oncoimmunology. 2015;4(12):e996475.
   PubMed Web of Science ®Google Scholar
• Sokol L, Caceres G, Volinia S, et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol. 2011;153(1):24–32.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Pelosi E, Castelli G, et al. A miRNA Signature in Human Cord Blood Stem and Progenitor Cells as Potential Biomarker of Specific Acute Myeloid Leukemia Subtypes. J Cell Physiol. 2015;230(8):1770–1780.
   PubMed Web of Science ®Google Scholar